Evaxion Biotech A/S — Form 6-K Summary
Business Context and Reporting Period
Evaxion Biotech A/S filed this Form 6-K for December 2022. The filing reports a regulatory milestone for EVX-01, the company’s personalized, peptide-based cancer immunotherapy for melanoma, and does not provide financial statements or period-specific financial results.
Key Financial and Operating Metrics
- Revenue, profit, cash flow and margins: The filing does not provide a clear value for these metrics.
- Debt and liquidity: The filing does not provide a clear value or update.
- Clinical development: EVX-01 is being evaluated in a global Phase 2b trial in combination with KEYTRUDA® (pembrolizumab) for adults with unresectable or metastatic melanoma.
Material Changes Versus the Prior Comparable Period
- On December 22, 2022, the FDA notified Evaxion that it had reviewed the company’s Investigational New Drug application and that the Phase 2b EVX-01 trial may proceed.
- The IND and a Fast Track designation request were submitted to the FDA in November 2022.
- The company had enrolled the first patient in Australia in September 2022.
- Clinical Trial Applications had been approved in Australia, Italy and France; the company subsequently informed French regulators that it did not currently intend to conduct the trial in France.
- A CTA was submitted in Spain, with approval pending from Spanish regulators.
Guidance, Outlook, Risks and Unusual Items
- Evaxion anticipated receiving the FDA’s response regarding Fast Track designation in the first quarter of 2023.
- The trial is expected to be conducted at sites across the United States, Europe and Australia in collaboration with Merck, which is supplying KEYTRUDA.
- Evaxion is responsible for conducting the trial, while the company and Merck will continue collaborating as data mature.
- The single-arm trial will assess the efficacy and safety of EVX-01 plus KEYTRUDA, including whether EVX-01 improves best overall response in patients initially achieving stable disease or partial response after starting KEYTRUDA, compared with historical outcomes for KEYTRUDA alone.
- Key risks include clinical efficacy and safety uncertainty, reliance on historical comparisons, regulatory and site-approval timelines, trial execution, and the possibility that Fast Track designation may not be granted.
Facts Investors Should Verify
- FDA authorization to proceed is not an approval of EVX-01’s safety or efficacy.
- Whether the FDA grants Fast Track designation in the first quarter of 2023.
- Enrollment progress, trial-site activation and regulatory approvals in Spain and other jurisdictions.
- Future clinical data, including response rates, safety outcomes and comparison with historical KEYTRUDA results.
- The company’s cash runway, financing requirements and financial condition, which are not disclosed in this filing.